IMR Press / FBL / Volume 23 / Issue 9 / DOI: 10.2741/4671

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target

Show Less
1 Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
2 Department of Hematology, Juntendo University Shizuoka Hospital, Nagaoka 1129, Izunokuni-city, Shizuoka 410-2295, Japan
3 Y’s AC Co., Ltd., 5-3-14, Toranomon, Minato-ku, Tokyo 105-0001, Japan
4 Department of Pathology, Keio University school of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
5 Department of Pathology, Saitama Medical University, 38 Morohongo, Moroyama-cho, Iruma-gun, Saitama 350-0459, Japan
6 Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road-Box 100278, Room MSB M410A, Gainesville, FL 32610, USA
Front. Biosci. (Landmark Ed) 2018, 23(9), 1754–1779;
Published: 1 June 2018
(This article belongs to the Special Issue Dipeptidyl peptidase IV and related molecules in health and disease)

CD26 is a 110 kDa surface glycoprotein with intrinsic dipeptidyl peptidase IV activity that is expressed on numerous cell types and has a multitude of biological functions. The role of CD26 in immune regulation has been extensively characterized, with recent findings elucidating its linkage with signaling pathways and structures involved in T-lymphocyte activation as well as antigen presenting cell-T-cell interaction. In this paper, we will review emerging data on CD26-mediated immune regulation suggesting that CD26 may be an appropriate therapeutic target for the treatment of selected immune disorders as well as Middle East respiratory syndrome coronavirus. Moreover, we have had a long-standing interest in the role of CD26 in cancer biology and its suitability as a novel therapeutic target in selected neoplasms. We reported robust in vivo data on the anti-tumor activity of anti-CD26 monoclonal antibody in mouse xenograft models. We herein review significant novel findings and the early clinical development of a CD26-targeted therapy in selected immune disorders and cancers, advances that can lead to a more hopeful future for patients with these intractable diseases.

Humanized anti-CD26 monoclonal antibody
Graft-versus-host disease
Malignant pleural mesothelioma
Back to top